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- A group of naphthofuro[3,2-c]quinoline and pyrano[3,2-c]quinoline derivatives were 
synthesized. 
- The compounds inhibited ERK in an ATP-competitive manner. 
- 3b and 6 exhibited pronounced cyctoxicity against the NCI-60 panel of human tumor cell lines. 
- 3b and 6 inhibited ERK in the A375 melanoma cell line, suppressed colony formation and 
induced apoptosis. 







Approximately 60% of human cancers exhibit enhanced activity of ERK1 and ERK2, reflecting 
their multiple roles in tumor initiation and progression. Acquired drug resistance, especially 
mechanisms associated with the reactivation of the MAPK (RAF/MEK/ERK) pathway represent 
a major challenge to current treatments of melanoma and several other cancers.  Recently, 
targeting ERK has evolved as a potentially attractive strategy to overcome this resistance. 
Herein, we report the design and synthesis of novel series of fused naphthofuro[3,2-c]quinoline-
6,7,12-triones (3a-f) and pyrano[3,2-c]quinoline-6,7,8,13-tetraones (5a-b and 6), as potential 
ERK inhibitors. New inhibitors were synthesized and identified by different spectroscopic 
techniques and X-ray crystallography. They were evaluated for their ability to inhibit ERK1/2 in 
an in vitro radioactive kinase assay. 3b and 6 inhibited ERK1 with IC50s of 0.5 and 0.19 µM, 
and inhibited ERK2 with IC50s of 0.6 and 0.16 µM respectively.  Kinetic mechanism studies 
revealed that the inhibitors are ATP-competitive inhibitors where 6 inhibited ERK2 with a Ki of 
0.09 µM. Six of the new inhibitors were tested for their in vitro anticancer activity against the 
NCI-60 panel of tumor cell lines. Compound 3b and 6 were the most potent against most of the 
human tumor cell lines tested. Moreover, 3b and 6 inhibited the proliferation of the BRAF 
mutant A375 melanoma cell with IC50s of 3.7 and 0.13 µM, respectfully.  In addition, they 
suppressed anchorage-dependent colony formation. Treatment of the A375 cell line with 3b and 
6 inhibited the phosphorylation of ERK substrates p-90RSK and ELK-1 and induced apoptosis in 
a dose dependent manner. Finally, a molecular docking study showed the potential binding mode 
of 3b and 6 within the ATP catalytic binding site of ERK.  
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The fused pyranoquinolines have a common structural motif, existing in many naturally 
occurring and biologically active alkaloids, such as flindersine, oricine, verprisine, and 
Araliopsis tabouensis alkaloids [1,2].  Several derivatives of these alkaloids are being used as 
pharmaceuticals and agrochemicals. They have been reported to exhibit a wide range of 
biological activities including anti-inflammatory, anti-allergic, psychotropic, and estrogenic 
effects [3]. Their broad biological activity has turned them into popular compounds for 
pharmacological studies [4-7]. Recent studies reported the successful construction of fused 
tricyclic pyranoquinolines, such as polycyclic using 4-hydroxyquinolone together with different 
activated ylidenes [8]. Moreover, a multicomponent system has also been used for synthesis 
based on fused pyranoquinolines [9, 10]. Derivatives of the 1,4-naphthoquinone pharmacophore 
are known to exhibit pronounced biological and pharmacological activities, including anti-
tumor[11], anti-proliferative [12], anti-mycobacterial [13], anti-platelet, anti-inflammatory, anti-
allergic [14], anti-malarial [15] and anti-leishmanial activities [16]. Substituted naphtho[2,3-
b]furan-4,9-diones inhibited hyperproliferation of human keratinocytes and could therefore be 
potentially useful in the treatment of psoriasis, a common, immune-mediated inflammatory 
disease [17].  
The high frequency of aberrant activity of the RAS/RAF/MEK/ERK cascade found in human 
cancers, makes this pathway a potential target for treatment [18, 19].  Several potent inhibitors, 
targeting RAF and MEK kinases have been widely used for BRAF- and RAS- mutant tumors, 
including vemurafenib, dabrafenib, trametinib and selumetinib [18].  However, tumor regrowth 
after an initial response is common and is attributed to several mechanisms [20, 21], commonly 
all involving ERK reactivation.  ERK corresponds to a pair of downstream kinases (ERK1 and 
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ERK2) and represents a terminal signal node for this pathway [22]. Several ERK inhibitors have 
been discovered and show an ability to overcome resistance [23].  For example, the potent ERK 
inhibitor BVD-523 (Ulixertinib) showed encouraging antitumor activity in in vitro and in vivo 
models of acquired resistance to BRAF and/or MEK targeted inhibitors [24].  A recent dose 
escalation in-human study of BVD-523, exhibited early evidence for clinical activity in NRAS- 
and BRAF V600-solid tumor malignancies with acceptable safety and pharmacokinetics 
behavior [19]. The apparent promise of ERK modulators in human cancer, especially the ones 
with acquired resistance to BRAF and/or MEK inhibition, encouraged our efforts towards 
developing a potent and selective ERK inhibitor.  
We have utilized the 2,3-dichloro-1,4-naphthoquinone (DCHNQ) moiety in several 
heterocyclic synthesis programs, including the synthesis of heterocycles having creatinine [25] 
and thiobarbituric acid [26]. In addition, we synthesized several naphtho-1,3-dithiole derivatives 
[27] and dibenzo[b,i]-thianthrene-5,7,12,14-tetraone derivatives [28].  In our previous studies, 
we synthesized a series of ethyl pyrano[3,2-c]quinoline-4-carboxylates [29], spiro(indoline-3,4'-
pyrano[3,2-c]-quinoline)-3'-carbonitriles [30], 2,3-bis-(4-hydroxy-2-oxo-1,2-dihydroquinolin-3-
yl)succinates and arylmethylene-bis-3,3’-quinoline-2-ones [31]. In addition to the synthesis of 
two series of N-2,3-bis(6-substituted-4-hydroxy-2-oxo-1,2-dihydroquinolin-3-yl)naphthalene-
1,4-diones and substituted N-(methyl/ethyl)bisquinolinone triethyl-ammonium, that been 
reported to inhibit ERK2 activity in an vitro kinase assay [32].  
In this current project we synthesized a novel series of fused naphthofuro[3,2-c]quinoline-
6,7,12-triones 3a-f and pyrano[3,2-c]quinoline-6,7,8,13-tetraones 5a-b and 6 from the reaction of 
1,6-disubstituted-4-hydroxy-quinoline-2-ones 1a-f and 4-hydroxy-pyrano[3,2-c]quinoline-
4,5(6H)-diones 4a-c with 2,3-dichloro-1,4-naphthoquinone (DCHNQ). The ability of the new 
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compounds to inhibit the ERK kinase activity was assessed in an in vitro kinase assay and in-
cells using western blotting. The cytotoxic activity of the synthesized compounds towards the 
NCI-60 panel of cancer cell lines was determined and the cellular mechanism of the most potent 
inhibitors was further investigated in A375 melanoma cell line.  Finally, the binding features of 
the synthesized compounds within the ATP-binding site of ERK2 was estimated using molecular 
docking studies. 
2. Results and Discussion 
2.1. Chemistry 
Upon mixing equivalent amounts of 2,3-dichloro-1,4-naphthoquinone (DCHNQ, 2) and 1,6-
disubstituted-4-hydroxy-quinoline-2-ones 1a-f, followed by refluxing in different solvents, such 
as: NaOEt/EtOH (Method I), pyridine (Method II) or DMF Method (III), 
naphtho[2',3':4,5]furo[3,2-c]quinoline-6,7,12(5H)-trione derivatives 3a-f were obtained as single 
products (Scheme 1A). Noticeably, the reaction in pyridine (Method II) afforded 3a-f in better 
yields (85-92%), if compared to the other two methods (Scheme 1A). Structure elucidation of 
compounds 3a-f was carried out by IR, 1H-NMR, 13C-NMR and mass spectrometry, as well as 
elemental analyses. The structures of 3c and 3f, were confirmed by X-ray structural analysis 
(Figure 1A and 1B). Afterward, we investigated the reactions of DCHNQ (2) and 4-hydroxy-
pyrano[3,2-c]quinoline-4,5(6H)-diones (4a-c) under the same conditions mentioned above 
(Scheme 1B). The reaction of 2 and 4a,b afforded two 5H-naphthalen-[2'',3'':4',5']-
furo[3',2':4',5,6]pyrano-[3,2-c]quinoline-6,7,8,13-tetraones derivatives 5a, b as single products. 




The chemical identities of 5a,b and 6 was confirmed by IR, 1H-NMR, 13C-NMR, mass 
spectrometry and elemental analyses.  
Structure elucidation of compounds 3a-f was carried out by IR, NMR and mass spectra, besides 
elemental analyses. For 3a, its gross formula C19H8ClNO4 represents a product from one molecule of 1a 
and one molecule of DCHNQ, 2 with elimination two molecules of HCl. Mass spectrum and elemental 
analysis proved the molecular formula of 3a as C19H9NO4. The IR spectrum of 3a showed four 
characteristic bands at  = 3210 (NH), 1700, 1660 (CO), 1596 (Ar-C=C). Resonated double-doublet, 
doublet and singlet were appeared in the 1H NMR spectrum of 3b at δH 7.65 (J = 7.0, 0.8 Hz) for H-3, 
7.50 (J = 0.7 Hz) for H-1 and δH 8.10 ppm for (NH). In 
13C NMR spectrum of 3f, the two carbonyl 
carbons appeared at δC = 176.0 and 173.0 ppm. Seven carbon signals were also distinguished in 
13C 
NMR of 3f absorbed at δC = 160.4, 132.7, 128.6, 127.7, 126.8, and 115.5.5 ppm assigned to C-6, C-9 
(C-10), C-3, C-1, C-8 (C-11) and C-4, respectively (Experimental section). The ethyl protons were 
absorbed in the 1H NMR spectrum at δH = 1.30 and 4.47 as quartet and triplet, whereas its carbons 
resonated in the 13C NMR spectrum at δC = 13.7 (CH3) and 47.8 ppm (CH2) (Experimental section). In 
the light of the above mentioned findings, we undertook to investigate the reactions of DCHNQ (2) with 
4-hydroxy-pyrano[3,2-c]quinoline-4,5(6H)-diones 4a-c under the same previous condition (Scheme 
1B). We have expected that reaction behaves similarly as in the reaction of 1a-f with 2. The structure of 
the obtained 5H-naphthalen-[2'',3'':4',5']-furo[3',2':4',5,6]pyrano-[3,2-c]quinoline-6,7,8,13-tetraones 5a,b 
(Scheme 1B) was only noted in case of the reaction between 4a,b and 2 (Scheme 1B). Whilst reaction of 
4c with 2 gave syn/anti-3-(1,4-dioxo-1,4-dihydronaphthalen-2-yl)-4-hydroxy-6-phenyl-2H-pyrano[3,2-
c]-quinoline-2,5(6H)-dione (6). Compound 6 was obtained as characteristically brown color crystals. Its 
molecular structure formula is C28H15NO6, represents a product from one molecule of DCHNQ and one 
molecule of 4c with loss one molecule of HCl. In 1H NMR spectrum, the low-field OH- attached to 
9 
 
pyrane ring is at δH =13.90 ppm. In 
13C NMR spectrum, the distinct carbons assigned as CO (C-1'), C-
OH, CO (C-2) and C-O, (C-5), resonated at C = 176.9, 166.1, 163.2 and 162.3 ppm, respectively. 
Scheme 1. (A). Different methods for preparation of naphthofuro[3,2-c]quinoline-6,7,12-triones 





Figure 1. The X-ray structural analysis of (A) 3c and (B) 3f and (C) 6. The X-ray structure of 
one of the two crystallographic independent molecules of 6, solvent omitted for clarity and 
displacement parameters are drawn at 50% probability level. (D) Resonance structures of 
quinolones 4a,b. 
 
The same conclusion was confirmed by single crystal X-ray analysis (Figure 1C). The basicity of the N-
quinolone lone pair in compounds 4a,b, is responsible for the nucleophilic character of the OH group 
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that enables the cyclization process. The former is related to the resonance structures I to III (Figure 
1D). Since the N-Ph derivative 4c is of lower basicity compared to 4a,b, the reaction stops at the step of 
replacement in the nucleophilic position-3 of the pyrano moiety (Figure 1D). 
 
Scheme 2. Mechanism described formation of compounds 3a-f 
The reaction mechanism can be described as nucleophilic attack of CH-3 in 1a-f to C-2 in 2 to 
form the Zwitter ion A (Scheme 2). Pyridine molecule would then enhance elimination of HCl 
from A to give intermediate B and pyridinium salt. Further nucleophilic attach from the oxygen 
lone pair to vinylic carbon in B would give Zwitter ionic intermediate C (Scheme 2). Ultimately, 
a second molecule of pyridine would catalyze the elimination of HCl to give 3a-f and pyridinium 
salt (Scheme 2). 
2.2. Biological evaluation 
2.2.1. Evaluation of the in vitro anticancer activity of the new compounds - Among the 
synthesized compounds, NCI selected compounds 3a, 3b and 3e from the fused naphthofuro[3,2-
c]quinoline-6,7,12-trione derivatives and 5a, 5b and 6 from the fused naphthofuro-pyrano[3,2-
c]quinoline-6,7,8,13-tetraone derivatives. Anticancer assays were performed according to the US 
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NCI protocol (The procedures of the assay are described at (http://www.dtp.nci.nih.gov). The 
compounds were tested against a panel of 60 cancer cell lines, derived from different tumors. 
Including leukemia, melanoma, lung, colon, central nervous system (CNS), ovarian, renal, 
prostate and breast cancer. The compounds were incubated with the cells at a concentration of 10 
µM for 48 h and the cells density were estimated using sulforhodamine B (SRB), a protein 
binding dye. The results were reported as the growth percent (G%) of the cells that were treated 
by each compound relative to the cells treated with vehicle, and relative to the number of cells 
present when the treatment with the compounds started (Table 1). On average, 3a, 3b and 3e 
exhibited inhibitory effects on most of the leukemia cell lines tested with varied responses. 
While, in the rest of the tested tumors, compound 3b showed much more pronounced growth 
suppressive activity, compared to 3a and 3e with an average G% of -4.7, 68 and 74 % 
respectively.  
Nevertheless, in a few cell lines strong growth inhibition and/or lethality were observed by 3a, 
specifically in the two leukemia cell lines HL-60(TB) and MOLT-4 and the ovarian cancer cell 
lines OVCAR-3 and OVCAR-4. Whereas 3e strongly suppressed the growth of the leukemia cell 
line MOLT-4 and the ovarian cancer cell line OVCAR-4. Interestingly, 3b was able to induce a 
broad tumor cell death for most of the non-small cell lung cancer, colon cancer, CNS cancer, 
melanoma, ovarian cancer, renal cancer and breast cancer cell lines (Table 1). Even in the cell 
lines where it was not toxic, 3b typically exhibited considerably more potent growth inhibition 
than 3a and 3e. Upon testing 5a, 5b and 6, compound 6 showed a major anti-proliferative effect 
on most of the tested cell lines, with average G% of 35%, whereas compound 5a and 5b showed 
little growth suppressive activity against most of the tested human cancer cell lines with average 
G1% of 65 and 95% respectively. For example, 5a induced cell death in few cell lines, including 
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two ovarian cancer cell lines OVCAR-3 and OVCAR-4, two leukemia cell lines HL-60 and 
MOLT-4, and one breast cancer cell lines MDA-MB-468. In addition, the growth of the 
leukemia cell line CCRF-CEM was almost completely inhibited by 5a.  
Table 1. Growth percent (G %) of the NCI-60 panel tumor cell lines at 10-5 M concentration of 
compounds 3a, 3b, 3e, 5a, 5b and 6 
  
Tumor cell lines 
                                                Growth Percent (G %) 
3a 3b 3e 5a 5b 6 
Leukemia    
CCRF-CEM 20.72 29.04 19.07 92.93 2.47 17.76 
HL-60(TB) 2.26 94.52 ND 104.29 -18.8 7.05 
K-562 55.20 12.90 68.79 89.61 28.57 26.84 
MOLT-4 5.55 18.44 2.39 87.37 -24.49 16.13 
RPMI-8226 62.72 4.83 51.06 100.23 33.49 19.65 
SR 43.80 33.72 ND 92.01 80.76 11.44 
Non-Small Cell Lung Cancer     
A549/ATCC 97.18 -0.05 81.67 85.17 82.36 37.73 
EKVX 27.35 15.17 70.67 ND ND ND 
HOP-62 118.63 -38.70 81.77 80.81 80.29 36.07 
HOP-92 71.42 -37.24 100.92 99.17 50.81 80.01 
NCI-H226 78.47 -28.80 73.22 88.55 99.44 86.30 
NCI-H23 65.95 21.21 78.33 86.15 66.79 38.22 
NCI-H322M 89.28 13.98 96.16 91.04 97.72 63.53 
NCI-H460 68.27 -69.73 78.50 108.09 83.68 33.57 
NCI-H522 54.81 -16.76 50.55 78.37 65.5 19.42 
Colon Cancer     
HCC-2998 102.57 65.07 101.82 103.64 100.59 42.85 
HCT-116 55.46 -12.24 71.69 99.77 34.6 41.72 
HCT-15 44.70 -31.10 85.01 94.13 79.63 66.56 
HT29 102.52 66.37 73.69 96.96 63.02 84.18 
KM 12      66.22 0.12 91.54 95.63 86.61 18.86 
SW-620 89.23 -53.04 86.24 103.1 73.47 18.61 
CNS Cancer     
SF-268 91.30 -31.69 95.35 101.09 84.32 34.32 
SF-295 92.71 -1.34 ND 101.32 95.07 18.38 
SF-539 90.30 -27.99 97.17 93.83 89.92 -5.45 
SNB-19 103.72 7.11 93.29 110.38 90.17 27.87 
SNB-75 112.98 -9.01 64.39 101.36 119.73 31.77 
U251 79.04 -77.55 90.22 104.35 57.67 21.15 
Melanoma     
LOX IMVI 56.12 11.13 76.59 95.89 32.39 42.99 
MALME-3M 124.29 -51.66 113.45 113.29 112.5 42.00 
M14 73.38 10.44 85.59 98.25 89.81 44.74 
MDA-MB-435 83.72 10.25 103.73 105.3 95.88 87.80 
SK-MEL-2 76.92 31.83 92.64 86.85 79.89 23.06 
SK-MEL-28 112.03 -11.84 111.89 107.21 106.96 39.37 
SK-MEL-5 79.73 12.31 76.95 97.56 67.42 17.66 
UACC-62 88.73 75.08 77.03 93.45 63.95 13.17 
Ovarian Cancer     
IGROV1 55.11 -3.63 68.65 65.92 68.31 71.85 
OVCAR-3 -14.81 -68.37 21.58 98.93 -16.31 2.15 
OVCAR-4 -5.49 -42.04 4.38 97.38 -99.52 18.80 
OVCAR-5 102.37 52.70 119.92 102.02 117.77 88.70 
OVCAR-8 35.61 -27.45 85.32 100.1 10.25 48.24 
SK-OV-3 104.46 1.64 93.55 95.03 102.05 67.28 
Renal Cancer     
A498 103.58 80.44 93.29 ND ND ND 
ACHN 65.70 -14.18 75.49 85.7 79.61 28.55 
RXF 393 97.24 -46.34 100.91 87.68 72.63 69.20 
SN12C 70.40 -26.26 81.84 125.68 106.07 -14.11 
UO-31 60.44 -54.91 54.76 137.02 112.5 64.18 
Prostate Cancer       
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 ND, Not determined 
As compound 3b exhibited the most pronounced inhibitory activity, it was further selected for 
advanced five dose testing, in which the cytotoxic and/or growth inhibitory effects of the 
compound were quantified in vitro against the full NCI-60 panel of human tumor cell lines using 
a series of five 10-fold dilutions, ranging from 10-4 M to 10-8 M. Three dose response parameters 
were calculated for each cell line, GI50 (molar concentration required for 50% growth inhibition), 
TGI (molar concentration leading to total growth inhibition), and LC50 (molar concentration 
resulting in 50% cell death).  
Table 2: The main cytotoxic parameters (GI50, TGI   and LC50) of compound 3b in µM. 
Tumor cell lines                 GI 50 TGI LC 50 
Leukemia 
CCRF-CEM 0.41 4.86 >100 
HL-60 (TB) 1.70 5.25 34.76 
K-562 0.37 2.00 50.12 
MOLT-4 0.44 3.16 >100 
RPMI-8226 0.39 2.63 >100 
SR 0.50 3.98 >100 
Non-Small Cell Lung Cancer 
A549/ATCC 1.02 2.88 8.32 
EKVX 0.25 2.45 26.30 
HOP-62 0.20 0.65 3.24 
HOP-92 0.15 0.39 1.00 
NCI-H226 0.14 0.35 0.87 
NCI-H23 0.35 1.82 7.08 
NCI-H322M 0.32 1.45 7.24 
NCI-H460 0.22 0.49 1.48 
NCI-H522 0.32 1.38 8.13 
Colon Cancer 
COLO 205 10.47 27.54 72.44 
HCC-2998 063 2.57 9.12 
HCT-116 0.31 1.10 4.57 
HCT-15 0.21 0.51 2.00 
HT29 3.72 12.88 39.81 
KM 12      0.45 3.02 27.54 
SW-620 0.33 1.00 7.59 
CNS Cancer  
SF-268 0.46 3.98 48.98 
SF-295 0.63 2.29 6.61 
SF-539 0.23 0.56 2.09 
SNB-19 0.31 1.10 6.17 
SNB-75 0.16 0.42 1.29 
U251 0.27 0.76 2.82 
Melanoma 
LOX IMVI 0.32 1.32 3.98 
MALME-3M 0.23 044 0.85 
M14 0.40 1.51 4.57 
PC-3 65.49 -33.26 64.38 79.23 81.82 49.16 
DU-145 82.02 -45.39 90.97 81.38 42.4 34.21 
Breast Cancer     
MCF7 48.82 0.70 68.38 76.73 92.37 51.60 
BT-549 73.94 37.99 77.38 104.21 93.67 12.26 
T-47D 22.52 -58.11 9.70 83.56 85.06 4.47 
MDA-MB-468 -8.43 -32.41 -9.91 64.82 -9.96 -27.29 
Average G% 68.19 -4.69 74.32 95.45 65.81 35.49 
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MDA-MB-435 0.30 1.20 4.07 
SK-MEL-2 1.74 5.13 19.95 
SK-MEL-28 0.34 1.23 4.68 
SK-MEL-5 1.30 1.20 3.72 
UACC-257 1.32 3.39 8.51 
UACC-62 0.28 1.15 3.98 
Ovarian Cancer 
IGROV1   0.22 0.74 3.47 
OVCAR-3 0.24 0.56 1.82 
OVCAR-4 0.17 0.45 1.51 
OVCAR-5 3.47 14.79 40.74 
OVCAR-8 0.39 2.29 30.20 
NCI/ADR-RES 0.35 1.78 34.67 
SK-OV-3 0.35 1.78 5.62 
Renal Cancer 
786-0 0.22 0.54 2.45 
A498 0.21 0.95 3.55 
ACHN 0.20 0.58 2.63 
RXF 393 0.21 0.58 2.51 
SN12C 0.20 0.47 1.35 
TK-10  0.38 1.10 6.03 
UO-31 0.19 0.60 2.51 
Prostate Cancer 
PC-3 0.18 0.46 1.58 
DU-145 0.28 0.78 12.30 
Breast Cancer 
MCF7 0.23 1.05 18.62 
MDA-MB-231/ATCC   0.17 0.51 2.82 
HS 578T 0.26 1.38 >100 
BT-549 0.30 1.32 6.76 
T-47D 0.26 0.98 5.13 
MDA-MB-468 0.25 0.87 4.57 
 
As Table 2 demonstrates, the results indicated that the selected active compound 3b showed 
broad spectrum anti-tumor activity against the nine tumor sub-panels tested. It exhibited strong 
growth inhibitory activity against all human cancer cell lines tested, with GI50 values mostly in 
the submicromolar range (0.14-10.47 µM, with an average across all cell lines tested of 0.24 
µM and only 7 cell lines showing GI50 values >1 µM) and TGI values typically in the low 
micromolar range (0.35-27.54 µM, with an average of 1.02 µM).  Importantly, compound 3b 
was also able to induce cell death in the vast majority of the cancer cell lines. The LC50 values 
ranged between 0.85 and 72.44 µM, with an average of 7.58 µM. The cytotoxic effects were 
strongest in the non-small cell lung cancer lines NCI-H226 (LC50=0.87 µM), HOP-92 (1.00 
µM) and NCI-H460 (1.48 µM), the CNS cancer line SNB-75 (1.29 µM), the melanoma line 
MALME-3M (0.85 µM), the ovarian cancer lines OVCAR-4 (1.51 µM) and OVCAR-3 (1.82 
µM), the renal cancer line SN12C (1.35 µM) and the prostate cancer line PC-3 (1.58 µM). 
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Notably, compound 3b was also lethal to nearly all of the remaining cancer cell lines, with only 
five of the lines in the NCI-60 panel not reaching 50% lethality within the concentration range 
tested (Table 2). In line with the results from the single dose screen, compound 3b was least 
efficient against leukemia cells, four of which exhibited an LC50 >100 µM. The promising 
anticancer activity observed by these new compounds may be attributed to their activity towards 
the ERK kinase pathway in these tested tumor cell lines. Accordingly, we decided to go further 
and test this hypothesis. 
2.2.2. The new compounds selectively inhibited ERK compared to other MAP kinases – 
From the anticancer screening results (Table 1), we selected compounds 3a, 3b and 6 to study 
their molecular mechanism in vitro and in cells.  Compound 5a was selected as a negative 
control compound. First, in an in vitro kinase assay, we tested the ability of these compounds to 
inhibit the activity of ERK1 and ERK2 towards a downstream substrate Ets-1 in the presence of 
100 µM ATP.  Figure 2A-D show dose response curves for ERK2 inhibition.  
As shown in Table 3, 3a, 3b and 6 inhibited ERK1 with IC50s of 9.12, 0.5 and 0.19 µM 
respectively while 3c inhibited ERK1 with much higher IC50 of 95 µM. Similar activities were 
observed for ERK2 with IC50s of 10.2, 0.6 and 0.16 µM respectively while 5a inhibited ERK2 
with IC50 > 100 µM. To profile the selectivity of these compounds we examined their ability to 
inhibit other MAP kinases, including JNK2 or p38MAPKα.  Compounds 3a and 5a did not show 
any ability to inhibit JNK2 or p38MAPKα (Table 3). Whereas compounds 3b and 6 showed little 
tendency to inhibit JNK2 and p38MAPKα (Figure 2E and F). Compound 3b inhibited JNK2 and 
p38MAPKα with IC50s of 24 µM and 28 µM, respectively, revealing a selectivity of around 50-
fold towards ERK. Compound 6 inhibited JNK2 and p38MAPKα with IC50s with IC50s of 4.2 





Figure 2. 3b and 6 are potent ERK inhibitors in in vitro cell-free kinase assays.  3a (A), 3b (B), 
5a (C) and 6 (D) inhibited Ets-1 phosphorylation by ERK2 in the in-vitro kinase assay. (E) The 
effect of 3b and 6 on the ability of JNK2 to phosphorylate GST-c-Jun (1-221). (F) The effect of 
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3b and 6 on the ability of p38MAPKα to phosphorylate GST-ATF2 (1-115). Data were fitted to 
Eq. 1 (Methods section). 
 













ERK1 (100 µM ATP) 9.12±1.1 0.5±0.09 95±10.9 0.19±0.01 
ERK2 (100 µM ATP) 10.2±1.2 0.6±0.1 108±12.2 0.16±0.02 
ERK2 (10 µM ATP)  0.2±0.01  0.086±0.005 
JNK2 >200 24±1.24 >200 4.2±0.9 
p38MAPKα >200 27.9±1.5 >200 3.1±0.5 
A375 Cell Viability  3.7±0.6  0.13±0.03 
aIC50 Determined as described in Methods section, Data were fitted to equation 1.   
Interestingly, the differential ability of the tested compounds to inhibit ERK activity in-vitro 
correlates to their cytotoxic activity that shown in table 1. 3b and 6 showed the most potent ERK 
inhibition and the most pronounced anticancer activity against most of the tested cell lines 
(average G% of -4.5% and 35% respectively) while compound 3a showed a modest ability to 
inhibit ERK activity with IC50 of around 9 µM (Table 3) and weak ability to impa ct the cancer 
cells growth at 10 µM concentration with average %G of 68% (Table 1). The inability of 5a to 
exhibit any considerable cytotoxic or anti-proliferative activity (average %G of 95%) was mainly 
attributed to its limited potency towards inhibiting ERK with IC50s of ≥ 100µM (Tables 1 and 
3).  
2.2.3. In vitro studies of the new inhibitors identify a mechanism of ATP-competitive  
          inhibition 
To understand the mechanism of ERK inhibition by the new compounds, we initially 
tested the effect of varying the concentration of Ets-1 on the ability of the inhibitors to suppress 
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ERK2 activity.  Using excess of Ets-1 (100 µM) did not rescue the inhibition of ERK2 by 5 µM 
of 3a, 3b or 6 (Figure 3A), as it showed a similar susceptibility to the inhibitors in presence of 10 
µM Ets-1 (the Km of Ets-1 towards ERK2 ~ 10 µM[33]), suggesting that the binding of the 
inhibitor does not impact the binding of Ets-1 to ERK2, which binds at the D and F-recruitment 
sites of ERK2[34, 35].  In order to examine the possibility that the inhibitors may bind the active 
site of ERK where ATP is known to bind, we determined the IC50s of 3b and 6 towards ERK2 
in the presence of 100 µM or 10 µM of ATP  (the Km of ATP towards ERK2 ~ 100µM[34]).   
 
Figure 3. Mechanism of ERK2 inhibition by the newly synthesized compounds.  (A) Higher 
concentrations of Ets-1 did not impact the ability of 3a, 3b, 5a and 6 to inhibit its 
phosphorylation by ERK2. 10 µM of each inhibitor were added to 2 nM of activated ERK2 in 
the presence of either 1 or 10-fold excess over the Km of Ets-1 and 100 µM ATP (B) Inhibition of 
ERK2 activity by 6 at varied fixed concentrations of Mg-ATP (10-2000 µM) and 50 µM Ets-1 
and (C) the double reciprocal plot of  vs 1/[Mg-ATP] at varied fixed concentrations of 6 (0-
54 µM) and  50 µM Ets-1.  Initial velocities were measured using various (10–2000 µM) 




to Eq. 2, where 

kcat
app = 11 ± 1.0 s-1, 

Km
a p p (ATP)= 63.4 ± 9.2 µM, 

Ki
a p p = 0.089 ± 0.1  µM (D) 
Inhibition constant and mechanism of inhibition of ERK2 by 6.  
The results shown in table 3 suggest that decreasing the concentration of ATP increased 
the ‘apparent’ potency of the inhibitor towards ERK2. Compound 3b showed an IC50 of 0.6 µM 
at 100 µM ATP and 0.2 µM in the presence of 10 µM ATP, while 6 showed an IC50 of 0.16 µM 
at 100 µM ATP and 0.09 µM in presence of 10 µM ATP. These observations represent the first 
evidence that these inhibitor bind ERK in the active site, where they are able to prevent ATP 
from reaching ERK. Furthermore, and to confirm this mechanism, we decided to determine the 
observed rate constant, kobs, over a range of ATP concentrations at different fixed concentrations 
of 6, in the presence of a saturating concentration of Ets-1 (50 µM).  The double reciprocal plot 
derived from this study (Figure 3C) is consistent with a mechanism of competitive inhibition, 
where Ki ~ 0.09±0.01 µM).  According to this model (Figure 3D). Compound 6 binds ERK and 
abrogates its affinity for ATP without affecting kcat.  The binding mode of 6 to the ERK active 
site impedes the recognition of ATP by the enzyme. 
2.2.4. Structure Activity Relationship 
Based on the structural features of the newly synthesized compounds, their cytotoxic 
activities and their ability to inhibit ERK2 activity in-vitro (Table 4), it is obvious that 
substituents on the quinolone moiety can alter the biological activity of these inhibitors. For 
example, substituent at N-quinoline moiety (R1 of 3a-f and R3 of 5a-b) seems to decrease their 
ability to inhibit ERK2 and to suppress their cytotoxic activity. Compound 3a (R1=H) showed 
better ability to inhibit ERK2 and to suppress tumor cell growth, compared to 3e and 3f that (R1 
= methyl and ethyl respectively).  This demonstrates the important role played by the free NH in 
the ability of the compounds to inhibit ERK2 and to exhibit anti-tumor activity. Noticeably, the 
size of R1 is inversely proportion to the ability to inhibit ERK2 in vitro, especially if we 
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compared the biological activities of 3a, 3e and 3f. Moreover, there is evidence that substituents 
at the 2 position of the quinolone ring can alter the biological activities of these new derivatives. 
Interestingly, 3b, that carries an electron withdrawing Cl at the R2 position showed very high 
potency towards ERK2 inhibition and tumor cell growth suppression (Table 4), while changing 
this group to Br (3c) or Me (3d) completely abrogated the ability of these inhibitors to affect 
ERK2 activity in vitro.  Finally, compound 6 that formed of a mixture of syn/anti isomers of 3-
(1,4-dioxo-1,4-dihydronaphthalen-2-yl)-4-hydroxy-6-phenyl-2H-pyrano[3,2-c]-quinoline-
2,5(6H)-dione, represents a different scaffolds from 3a-f or 5a-b, its potent inhibition of ERK2 
activity (IC50 ~ 0.16 µM) and tumor growth (average G% ~ 35% at 10µM treatment) suggest 
that its binding mode to ERK2 and its selectivity profile can be different from compounds 3 and 
5. 





 µM)( a50IC 
at 
100 µM ATP  





G%  1R 2R 3R 4R 
3a -H -H   10.2±1.2 68 
3b -H -Cl   0.6±0.1 -4.5 
3c -H -Br   >100 ND 
3d -H -Me   59±8.2 ND 
3e -Me -H   21±5.6 74 
3f -Et -H   >100 ND 
5a   -Me -H >100 95 
5b   -Et -H 8.3±1.5 65 
6     0.16±0.02 35 
ND, Not determined 
aIC50 Determined as described in Methods section, Data were fitted to equation 1.   
 
2.2.5. Cellular studies in the BRAFV600E mutant human melanoma cell line A375. 
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Inhibition of ERK activity towards the downstream substrates – Melanomas that carry 
activating BRAF and NRAS mutations exhibit constitutive ERK activity that is known to drive 
tumorigenesis. Inhibition of ERK activity has been reported to alter the proliferation of 
melanoma cell lines and inhibit the growth of melanoma tumors[36].   
 
Figure 4. Effect of compounds on BRAF-mutant A375 melanoma cell line A. 6 and 3b 
inhibited Elk and p90RSK phosphorylation in the BRAF-mutant A375 melanoma cell line. A375 
melanoma cells were treated with a DMSO control, different concentrations of 6 or 3b (0.5-25 
µM) for 12 hours in serum free media.  The MAP kinase pathway was then induced by the 
addition of EGF (100 nM) for 15 minutes before lysing the cells. Lysates were fractionated by 
SDS PAGE (10 % gel) and subjected to western blot analysis in order to detect the 
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phosphorylated forms of p-90RSK, ELK, ERK, MEK1/2 and JNK. B. 6 is a more potent 
inhibitor of A375 melanoma cell viability than 3b. Cells were treated with different doses of 
each inhibitor and incubated for 72 hours before analysis by the MTS assay. C. 6 and 3b 
inhibited BRAF-mutant A375 cells anchorage-dependent growth in a dose dependent manner 
(Cells were treated as described in the methods section).  
Treatment of A375 cells (melanoma cell line expressing BRAFV600E) with 3b or 6, followed 
by EGF stimulation resulted in a dose-dependent inhibition of the ERK substrates (p90RSK and 
ELK) phosphorylation. With no effect on ERK or MKK1/2 phosphorylation or the JNK pathway 
(Figure 4A). 10 µM of compound 6 was enough to inhibit p-90RSK phosphorylation while 2.5 
µM was enough to inhibit ELK phosphorylation. Compound 3b inhibited p90RSK at a 
concentration of 25 µM, while inhibited p-ELK at 10 µM. Notably, the cellular potencies of the 
tested compounds matched their relative activity in the in vitro kinase assay. 
Effect of the inhibitors on A375 cell viability and colonies formation – It has been 
reported that the clinical efficacy that can be produced by any drug targeting the ERK pathway 
becomes significant after at least 80 % ERK signaling is suppressed.[37] And the degree of ERK 
inhibition is directly correlated to the inhibition of melanoma cell proliferation.[36] The western 
blotting experiments emphasized the ability of the new inhibitors to inhibit ERK activity in the 
A375 cell line.  To assess the selectivity of 3b and 6 in this cell line, we evaluated their 
antiproliferative activity. 3b and 6 inhibited A375 proliferation (MTS assay) with IC50s of 3.7 
and 0.13 µM, respectively (Figure 4B and Table 3). Next, we tested the biological effect of these 
inhibitors on anchorage independent colony formation in soft agar (Figure 4C) that is known to 
be regulated by ERK kinase activity in melanoma cell lines[38]. Compound 6 started to inhibit 
melanoma cell colony forming ability at a concentration of 2.5 µM while 3b showed inhibition at 
10 µM. 
Effect of the compounds on the Proliferation rate of A375 Melanoma cell line - ERK has 
been shown to directly regulate over 100 known cellular targets (e.g. as pRSK, MYC and BIM) 
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that together control tumor cell proliferation, survival, and apoptosis [22]. To test the new 
inhibitors in a real time proliferation study A375 cells were treated with different dose of each 
inhibitor and the real time growth confluence was recorded every 1 hour for a total of 90 hours 
using an IncuCyte Zoom microscope. 3b and 6 showed dose-dependent inhibition of A375 
proliferation (Figure 5A and C) with compound 6 exhibiting the higher potency, compared to 3b.  
Apoptosis induction – Melanoma that carry BRAF mutations tends to be more resistant to 
apoptosis. ERK inhibition has been shown to induce apoptosis in such resistant melanoma.[39]. 
 
Figure 5. The tested compounds inhibited BRAF-mutant A375 melanoma cell proliferation and 
induced apoptosis.  (A-B) IncuCyte analysis of real time growth confluence (imaged every 1 
hour) showed dose-response inhibition of A375 growth rates by 6 and 3b, cells were treated with 
25 
 
different doses of each inhibitor before starting the IncuCyte imaging. Error bars: SEM (n = 3). 
(C-D) Treatment of 6 and 3b increases the rate of apoptosis of BRAF-mutant A375 melanoma 
cells in a dose-dependent manner. Cells were treated with different doses of each inhibitor, 
apoptosis was assessed using the lncuCyte Caspase 3/7 reagent and lncuCyte® ZOOM 
equipment with a × 10 objective at indicated time points. (E) 6 and 3b induced PARP cleavage 
in A375 cells. Cells were exposed to different doses of each inhibitor for 12 hours before cell 
lysis. Protein expression of PARP and cleaved PARP were analyzed by western blot using 
vinculin as a loading control. (Experiment was repeated two times).   
To determine the ability of the new compounds to induce apoptosis, we performed a single cell 
assay using the IncuCyte microscope.  A375 cells were treated with different doses of each 
inhibitor, plus a fixed concentration of the IncuCyte Caspase3/7 reagent that quantifies the 
activity of cellular caspase3/7.  Stained cells were imaged and counted using the IncuCyte 
microscope.  Interestingly, compounds 3b and 6 exhibited activation of caspase 3/7 in A375 cell 
line, at doses of 3.7 and 33.3 µM after 48 and 72 hours of incubation (Figure 5B and D).  
Moreover, treatment of A375 cells with compound 3b or 6 resulted an increase in cleaved PARP, 
another marker of apoptosis induction.[39]. These data support the notion that the induction of 
apoptosis by these inhibitors is a major mechanism of death that results from ERK pathway 
inhibition. 
2.3. Molecular docking calculations 
To reveal the binding features of the synthesized compounds with ERK2, molecular 
docking calculations were performed on the most potent compounds towards the ATP-active site 
of ERK2 using Autodock4.2 software.[40]. Autodock performance was first validated on an 
ERK2 crystal structure in complex with a tetrahydropyridopyrimidine amine derivative (N-[(1S)-
1-(3-chloro-4-fluorophenyl)-2-hydroxyethyl]-2-(tetrahydro-2H-pyran-4-ylamino)-5,8-
dihydropyrido[3,4-d]pyrimidine-7(6H)-carboxamide) or 2SH that been reported previously as an 
ATP competitive inhibitor of ERK [41] (PDB code: 4O6E [41]). Self-docking of 2SH was 
performed and the corresponding binding mode was investigated. Compared to the crystal 
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structure of 2SH-ERK2 complex, Autodock accurately predicted the binding mode of 2SH 
inside the ERK2 active site, forming five essential hydrogen bonds with Lys42, Met108, Lys114 
and Asp167. Molecular docking of the synthesized compounds 3a, 3b, 3e and 6 towards the 
active site of ERK2 was then performed and the corresponding binding energies and features 
were investigated. According to the docked 3a-ERK2 structure (Figure 6), 3a forms two essential 
hydrogen bonds with Met108 with bond lengths of 2.74 and 2.88 Å. Further interactions 
including van der Waals and hydrophobic interactions were observed, giving a total docking 
score of -8.34 kcal/mol. Introduction of a chlorine atom in the 2-position of the quinolone ring 
increased the binding energy of compound 3b, relative to the unsubstituted compound 3a, giving 
a binding score of -8.82 kcal/mol. The higher binding energy of compound 3b was attributed to 




Figure 6. Molecular docking of the synthesized compounds 3a, 3b, 3e and 6 towards                  
ATP-active site of ERK2. 
Additionally, introduction of a methyl group on the N-quinoline moiety resulted in lower binding 
energy of compound 3e (calc. -7.88 kcal/mol). This demonstrates the important role played by 
the free NH for the formation of the essential hydrogen bond with Met108. Compared to 
compound 3 derivatives, compound 6 showed better affinity towards ERK2 with docking score 
of -9.22 kcal/mol. The investigation of the binding mode of compound 6 with ERK2, suggested a 
different binding mode from compound 3 derivatives. The molecular docking model revealed 
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that compound 6 formed two hydrogen bonds between the pyrano ring and Met108 and the 
naphthalene ring and Lys114, with bond lengths of 2.86 and 2.81 Å, respectively (Figure 6). 
2.4. Drug likeliness and oral bioavailability 
Application of in silico computational technology during drug discovery and 
development offers considerable potential for reducing the number of experimental studies 
required for compound selection and development. Lipinski’s rule of five is commonly used in 
drug design and development to predict oral bioavailability of potential lead or drug molecules. 
Table 5: Pharmacokinetic prediction of the synthesized compounds by Molinspiration v2016.10  
Compound miLog Pa  TPSAb nONc nOHNHd nviolation Nrotbe Mol Volf MWtg %ABSh 
3a 3.08 80.14 5 1 0 0 256.10 315.28 81.35% 
3b 3.73 80.14 5 1 0 0 269.63 349.73 81.35% 
3c 3.86 80.14 5 1 0 0 273.98 394.18 81.35% 
3d 3.50 80.14 5 1 0 0 272.66 329.31 81.35% 
3e 3.59 69.29 5 0 0 0 273.04 329.31 85.09% 
3f 3.97 69.29 5 0 0 1 289.84 343.34 85.09% 
5a 4.39 99.50 7 0 0 1 334.38 411.37 74.67% 
5b 4.02 99.50 7 0 0 0 317.58 397.34 74.67% 
6 4.93 106.59 7 1 0 2 395.84 495.87 72.23% 
.octanol and water (miLogP)-Logarithm of partition coefficient between n a 
.Topological polar surface area (TPSA) b 
.ON)-Number of hydrogen bond acceptors (n c 
.OHNH)-Number of hydrogen bond donors (n d 
.rotb)-Number of rotatable bonds (n e 
.Percentage of absorption (%ABS) h.  Molecular weight (MWt) g. Molecular Volume f 
 
Molinspiration cheminformatics, (http://www.molinspiration.com) online software calculation 
toolkit, was used to determine the physicochemical parameters e.g. lipinski’s parameters, 
topological polar surface area (TPSA) and percentage of absorption (% ABS) of the synthesized 
compounds. The absorption percentage was calculated by using the following formula: % ABS= 
109 - [0.345x TPSA] [42]. According to Lipinski’s ‘‘rule of five’’, a candidate molecule will 
likely to be orally active, if the molecule satisfies the following rule [43]: i) the calculated 
octanol/water partition coefficient (Log P) < 5, ii) the molecular weight is under 500, iii) number 
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of hydrogen bond acceptors (notably N and O) ≤ 10, iv) number of hydrogen bond donors (OH 
and NH groups) ≤ 5.  Molecules violating more than one of these rules may have problems with 
bioavailability (Table 5).[43] Gratifyingly, on close inspection of Table 5, all the synthesized 
compounds were found to be in compliance with Lipinski rule of five. The milog 𝑃 valve of all 
compounds was found below five, suggesting that the molecules have good permeability across 
the cell membrane which in turn is needed for generation of bioactivity. Molecular weight was 
found to be less than 500 and thus these molecules are predicted to be easily transported, 
diffused and absorbed.  In addition, the number of hydrogen bond donors and acceptors were less 
than 5 and 10, respectively, thus these values are in accordance with Lipinski’s rules. TRSA of 
all titled compounds are observed in the range of (80.14-106.59˚A) which is below the limit 
160˚A, which is a very good indicator of the bioavailability of the synthesized compounds.  
Meanwhile, the calculated percentage of absorption of all derivatives ranged between (72.23- 
85.09%), demonstrating that they may have good cell membrane permeability and oral 
bioavailability.  
3. Conclusions 
A group of novel fused naphthofuro[3,2-c]quinoline-6,7,12-triones and 
naphthofuropyrano [3,2-c]quinoline-6,7,8,13-tetraones were synthesized and characterized based 
on different spectral data, as well as X-ray crystallography for some of the compounds. Six 
compounds were selected for in vitro anticancer screening against the NCI-60 panel of cancer 
cell lines. Most of the tested compounds showed growth inhibitory activity against at least a 
subset of the human tumor cell lines at a concentration of 10 µM. Compounds, 3b and 6 had the 
strongest cytotoxic activity, against the majority of the tested cell lines. To confirm the targeting 
of the ERK pathway by these inhibitors, we tested all the derivatives in an in vitro kinase assay 
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for ERK2. 3b and 6 showed the most potent activity towards ERK2 with IC50s of 0.6 and 0.16 
µM respectively. 3b exhibited 50-fold selectivity towards ERK2, when compared to other MAP 
kinases while 6 showed 20-fold selectivity. The in vitro kinetic mechanism studies revealed an 
ATP competitive mechanism of inhibition by the new compounds towards ERK. The structure-
activity study emphasized that substitution within the quinolone can alter the activity of the 
compounds towards ERK. The promising potency of 3b and 6 towards ERK, makes it important 
to investigate the possible utilization of these inhibitors in RAF mutant melanoma. As a model, 
we used the A375 cell line that carries the BRAFV600E activating mutant that is known to 
hyperactivate the ERK pathway. 3b and 6 inhibited ERK substrate phosphorylation in this cell 
line in a dose-dependent manner. Treating the cells with these inhibitors resulted in potent 
inhibition of cell proliferation and real time cell growth.  3b and 6 were potent enough to 
suppress A375 colony formation (a marker for tumorigenesis), that is known to be regulated by 
the ERK pathway and induced apoptosis. Finally, the molecular docking results indicated that 
compounds 3b and 6 have better affinity towards the ATP-active site of ERK2 with docking 
scores of -8.82 and -9.22, respectively. Furthermore, this work demonstrates that all the 
synthesized compounds adhere to the Lipinski rule of five, that is, the synthesized compounds 
are expected to have good oral bioavailability and a good pharmacokinetic profile. The 
inhibitor’s ability to manipulate ERK signaling in this type of melanoma cell line that harbors 
constitutive ERK activity, suggests that they represent a valuable group of ERK inhibitors that 
can be improved by further medicinal chemistry efforts. 
4. Material and Methods 
4.1. Chemistry 
Melting points, using open glass capillaries on a Gallenkamp melting point apparatus (Weiss-
Gallenkamp, Loughborough, UK), were measued without applying any corrections. The IR 
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spectra were recorded from potassium bromide disks with a FT divece. 1H and 13C NMR spectra 
were measured with a Bruker Avance (400 MHz for 1H, and 100 MHz for 13C), Institute of 
Organic Chemistry, Karlsruhe Institute of Technology (KIT), Karlsruhe, Germany. The 1H and 
13C chemical shifts are given relative to internal standard TMS. Coupling constants are stated in 
Hz, 1H-coupled 13C spectra were measured using gated decoupling. Correlations were 
established using 1H-1H COSY, HMBC and HSQC experiments. Mass spectrometry was 
performed by electron impact at 70 eV, (FAB-MS): Finnigan MAT 95, Institute of Organic 
Chemistry, Karlsruhe Institute of Technology, Karlsruhe, Germany. Mass spectra were recorded 
on Finnigan Fab, 70 eV. TLC was performed on analytical Merck 9385 silica aluminum sheets 
(Kieselgel 60) with Pf254 indicator; TLC's were viewed max = 254 nm. Elemental analyses were 
carried out at the Microanalytical Center, Cairo University, Egypt. 
4.1.1. Starting materials 
1,6-Disubstituted-4-hydroxy-quinoline-2-ones 1a-f were prepared as previously described. [44, 
45] 4-Hydroxy-pyrano[3,2-c]quinoline-4,5(6H)-diones 4a-c were prepared according to 




4.1.2. General Procedure 
A mixture of 1a-f (0.1 mol) or 4a-c (0.1 mol) and DCHNQ (2, 0.1 mol) in 20 mL (10% NaOEt 
as 1 g Na in 10 mL EtOH), pyridine (10 mL) or DMF (30 mL), was refluxed with stirring. The 
time peroid until the reactants had disappeared, as mentioned in Scheme 1A and Scheme 1B, was 
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monitored by TLC. The resulting precipitate was filtered off, washed with ethanol, and 
recrystallized to give pure crystals of 3a-f, 5a,b and 6. 
4.1.2.1. Naphtho[2',3':4,5]furo[3,2-c]quinoline-6,7,12(5H)-trione (3a). Yellow crystals 
(DMF/EtOH), yield: 0.284 g (90%), mp > 360 °C; IR (KBr): 3210 (NH), 1700, 1660 (CO), 1596 
(Ar-C=C) cm-1; 1H NMR (400 MHz, DMSO-d6):H 7.50-7.56 (m, 2H, Ar-H), 7.65-7.70 (m, 2H, 
Ar-H), 7.75-7.80 (m, 2H, Ar-H), 8.00 (s, 1H, NH), 8.12-8.20 (m, 2H, H-9,10); 13C NMR (100, 
DMSO-d6):C 176.2 (C-7), 173.0 (C-12), 169.1 (C-13a), 160.8 (C-6), 156.3 (C-12a), 136.4 (C-
4a), 133.1 (C-6b), 132.7 (C-9, C-10), 132.0 (C-11a), 130.7 (C-6a), 128.9 (C-3), 128.4 (C-7a, C-
13b), 127.7 (C-1), 126.6 (C-8, C-11), 124.8 (C-2), 116.0 (C-4); MS (Fab, 70 eV,%): m/z 315 
(M+, 100). Anal. Calcd. for C19H9NO4: C, 72.38; H, 2.88; N, 4.44. Found: C, 72.51; H, 3.01; N, 
4.39.  
4.1.2.2. 2-Chloronaphtho[2',3':4,5]furo[3,2-c]quinoline-6,7,12(5H)-trione (3b). Yellow 
crystals (DMF/H2O), yield: 0.307 g (88%), mp = 330-2 °C; IR (KBr): 3210 (NH), 3065 (Ar-CH), 
1700, 1667 (CO), 1593 (Ar-C=C) cm-1; 1H NMR (400 MHz, DMSO-d6):H 7.50 (d, 1H, J = 0.7 
Hz, H-1), 7.65 (dd, 1H, J = 7.0, 0.8 Hz, H-3), 7.86-7.90 (m, 3H, Ar-H), 8.10 (s, 1H, NH), 8.15-
8.20 (m, 2H, Ar-CH); 13C NMR (100 MHz, DMSO-d6):C 176.4 (C-7), 173.0 (C-12), 169.2 (C-
13a), 160.2 (C-6), 156.3 (C-12a), 134.5 (C-4a), 133.1 (C-6b), 132.7 (C-9), 132.0 (C-10), 132.2 
(C-11a), 130.3 (C-6a), 130.4 (C-2), 129.8 (C-13b), 129.0 (C-3), 128.4 (C-7a), 127.6 (C-1), 126.6 
(C-8, C-11), 123.5 (C-4); MS (Fab, 70 eV,%): m/z 351 (M+2, 38), 349 (M+, 100). Anal. Calcd. 
for C19H8ClNO4: C, 65.25; H, 2.31; N, 4.01. Found: C, 65.36; H, 2.19; N, 3.98. 4.1.2.3. 2-
Bromonaphtho[2',3':4,5]furo[3,2-c]quinoline-6,7,12(5H)-trione (3c). Yellow crystals 
(DMF/DMSO), yield: 0.334 g (85%), mp = 330-2 °C; IR (KBr): 3195 (NH), 3065 (Ar-CH), 
1696, 1667 (CO), 1593 (Ar-CH) cm-1; 1H NMR (400 MHz, DMSO-d6):H7.37 (d, 1H, J = 0.8 
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Hz, H-1), 7.75 (dd, 1H, J = 7.0, 0.8 Hz, H-3), 7.86-7.92 (m, 3H, Ar-H), 8.10-8.15 (m, 2H, Ar-H), 
8.25 (bs, 1H, NH); 13C NMR (100 MHz, DMSO-d6):C 176.5 (C-7), 173.0 (C-12), 169.2 (C-
13a), 160.1 (C-6), 156.0 (C-12a), 135.2 (C-4a), 133.1 (C-1), 132.8 (C-6b), 132.4 (C-9, C-10), 
131.6 (C-11a), 131.2 (C-3), 130.5 (C-6a), 130.0 (C-13b), 128.2 (C-7a), 126.6 (C-8, C-11), 124.2 
(C-4), 117.4 (C-2); MS (Fab, 70 eV,%): m/z 394 (M+, 36), 392 (M+, 100), 351 (65), 352 (55). 
Anal. Calcd. for C19H8BrNO4: C, 57.89; H, 2.05; N, 3.55. Found: C, 58.02; H, 2.11; N, 3.47.  
4.1.2.4. 2-Methylnaphtho[2',3':4,5]furo[3,2-c]quinoline-6,7,12(5H)-trione (3d). Yellow 
crystals (CHCl3/hexane), yield: 0.302 g (95%), mp > 360 °C; IR (KBr): 3194 (NH), 3060 (Ar-
CH), 2921-2810 (Aliph.-CH), 1687, 1665 (CO), 1590 (Ar-C=C) cm-1; 1H NMR (400 MHz, 
DMSO-d6):H2.30 (s, 3H, CH3), 7.20 (dd, 1H, J = 7.0, 1.0 Hz, H-3), 7.72 (d, 1H, J = 0.8 Hz, H-
1), 7.80-7.90 (m, 3H, Ar-CH), 8.20-8.25 (m, 3H, Ar-H, NH); 13C NMR (100 MHz, DMSO-
d6):C 176.0 (C-7), 173.0 (C-12), 169. 0 (C-13a), 160.8 (C-6), 156.3 (C-12a), 134.1 (C-5), 133.2 
(C-4a), 133.0 (C-6b), 132.6 (C-9, C-10), 132.0 (C-11a), 130.4 (C-6a), 130.2 (C-1), 129.0 (C-3), 
128.2 (C-7a), 128.0 (C-13b), 126.5 (C-8, C-11), 122.0 (C-4), 21.6 (CH3); MS (Fab, 70 eV,%): 
m/z 329 (M+, 100), 90 (10). Anal. Calcd. for C20H11NO4: C, 72.95; H, 3.37; N, 4.25. Found: C, 
72.88; H, 3.55; N, 4.13.  
4.1.2.5. 5-Methylnaphtho[2',3':4,5]furo[3,2-c]quinoline-6,7,12(5H)-trione (3e). Yellow 
crystals DMF/MeOH, yield: 0.282 g (91%), mp 350-2°C; IR (KBr): 3060 (Ar-CH), 2940-2870 
(Aliph.-CH). 1699, 1671 (CO), 1590 (Ar-C=C) cm-1; 1H NMR (400 MHz, DMSO- d6):H3.75 
(s, 3H, CH3), 7.40-7.50 (m, 2H, Ar-CH), 7.70-7.73 (m, 2H, Ar-CH), 8.00-8.34 (m, 4H, Ar-H); 
13C NMR (100 MHz, DMSO-d6):C 176.5 (C-7), 173.0 (C-12), 169.2 (C-13a), 161.1 (C-6), 
156.3 (C-12a), 134.3 (C-4a), 133.1 (C-6b), 132.7 (C-9, C-10), 132.0 (C-11a), 130.7 (C-6a), 
128.9 (C-3), 128.4 (C-7a, C-13b), 127.7 (C-1), 126.6 (C-8, C-11), 124.8 (C-2), 115.5 (C-4), 37.9 
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(CH3); MS (Fab, 70 eV,%): m/z 329 (M
+, 100), 90 (15). Anal. Calcd. for C20H11NO4: C, 72.95; 
H, 3.37; N, 4.25. Found: C, 73.08; H, 3.33; N, 4.43. 
4.1.2.6. 2-Ethylnaphtho[2',3':4,5]furo[3,2-c]quinoline-6,7,12(5H)-trione (3f). Yellow 
crystals, yield: 0.326 g (95%), mp 310 °C; IR (KBr): 3036 (Ar-CH), 2290 (Aliph.-CH), 1688, 
1670 (CO), 1582 (C=C) cm-1; 1H NMR (400 MHz, DMSO-d6):H 1.30 (t, 3H, J = 7.0 Hz, CH3), 
4.47 (q, 2H, CH2, J = 7.0 Hz ), 7.45-7.50 (m, 2H, Ar-CH), 7.65-7.70 (m, 2H, Ar-H), 7.88-7.94 
(m, 4H, Ar-H); 13C NMR (100 MHz, DMSO-d6):C 176.0 (C-7), 173.0 (C-12), 169.0 (C-13a), 
160.4 (C-6), 156.2 (C-12a), 134.2 (C-4a), 133.0 (C-6b), 132.7 (C-9, C-10), 132.0 (C-11a), 130.8 
(C-6a), 128.6 (C-3), 128.4 (C-7a, C-13b), 127.7 (C-1), 126.6 (C-8, C-11), 124.8 (C-2), 115.5 ( C-
4), 47.8 (CH2), 13.7 (CH3); MS (Fab, 70 eV,%): m/z 343 (M
+, 100). Anal. Calcd. for C21H13NO4: 
C, 73.46; H, 3.82; N, 4.08. Found: C, 73.29; H, 3.75; N, 4.25.  
4.1.2.7. 5-Methyl-5H-naphthalen[2'',3'':4',5']furo[3',2':4',5,6]pyrano[3,2-c]quinoline-
6,7,8,13-tetraone (5a). Yellow crystals, yield: 0.342 g (86%), mp 315 °C; IR (KBr): 3044 (Ar- 
CH), 2985 (Aliph.-CH), 1730, 1715, 1679 (CO), 1600, 1594 (Ar-C=C) cm-1; 1H NMR (400 
MHz, DMSO-d6):H 3.4 (s, 3H, N-CH3), 7.45-8.21 (m, 8H, Ar-H); 13C NMR (1000 MHz, 
DMSO-d6):C 176.0, 173.0, 170.2, 162.0 (CO), 160.0, 156.0, 135.1, 134.2, 133.0 (Ar-C), 132.4 
(Ar-2CH), 128.0 (Ar-C), 127.7, 126.8, 126.6 (Ar-CH), 126.0, 125.0 (Ar-C), 124.0, 122.8, 116.2 
(Ar-CH), 115.8, 115.4 (Ar-C), 29.0 (CH3-N-methyl); MS (Fab, 70 eV,%): m/z 397 (M
+, 100). 
Anal. Calcd. for C23H11NO6: C, 69.53; H, 2.79; N, 3.53. Found: C, 69.66; H, 2.81; N, 3.45. 
4.1.2.8. 5-Ethyl-5H-naphthalen[2'',3'':4',5']furo[3',2':4',5,6]pyrano[3,2-c]quinoline-
6,7,8,13-tetraone (5b). Yellow crystals, yield: 0.361 g (88%), mp 308 °C; IR (KBr): 3190 (Ar-
CH), 2980 (Aliph-CH), 1730, 1720, 1669 (CO), 1605, 1585 (Ar-C=C) cm-1; 1H NMR (400MHz, 
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DMSO-d6): H = 8.19-8.16 (m, 3H), 7.94-7.92 (m, 2H), 7.80-7.78 (m, 2H), 7.47 (dd, 1H, J = 6.8, 
6.4), 4.42 (q, 2H, J = 6.9 Hz), 1.29 (t, 3H, J = 6.9 Hz); 13C NMR (100 MHz, DMSO-d6): C = 
177.9 (C=O, C-8), 174.7 (C=O, C-13), 173.6 (C=O, C-7), 162.3 (C=O, C-6), 158.1 (C-15A), 
155.6 (C-14A), 153.1 (C-13A), 138.9 (C-4A), 134.5 (C-7B, HSQC H 7.94), 134.0 (C-12A), 
133.3 (C-11), 132.7 (C-10, HSQC H 7.80), 126.9 (C-3), 126.8 (C-9, HSQC: H = 8.19), 126.0 
(C-12), 125.9 (C-2), 124.2 (C-2), 122.8 (C-8A), 122.3 (C-7A), 115.8 (C-6A, HSQC: H = 7.47), 
111.5 (C-6A), 110.7 (C-4), 37.1 (CH2, HSQC: H = 4.42), 12.8 (CH3, HSQC: H = 1.29). MS 
(Fab, 70 eV, %): m/z 411 (M+, 25), 89 (22). Anal. Calcd. for C24H13NO6: C, 70.07; H, 3.19; N, 
3.40. Found: C, 70.22; H, 3.33; N, 3.55. 
4.1.2.9. 3-(3-Chloro-1,4-dioxo-1,4-dihydronaphthalen-2-yl)-4-hydroxy-6-phenyl-2H-
pyrano[3,2-c]quinoline-2,5(6H)-dione (6). Brown crystals, yield: 0.457 g (92%), mp 280 °C; 
IR (KBr): 3441 (OH), 3044 (Ar-CH), 1727, 1676 (CO), 1594 (Ar-C=C), cm-1; 1H NMR (400 
MHz, DMSO-d6):H 13.90 (br, s, 1H, OH), 8.50-7.50 (m, 13H, Ar-H); 13C NMR (100 MHz, 
DMSO-d6):C 179.9, 177.0 (CO), 166.1 (C-OH), 163.2 (CO, C-2), 162.3 (CO, C-5), 157.8 (C-
10a), 145.9 (C-2'), 140.3 (Ph-C), 138.4 (C-6a), 135.3 (C-4'a, 8'a), 132.0, 131.2, 131.0, 130.3 (Ar-
CH), 130.0, 128.2, 127.1, 124.6 (Ar-2CH), 122.6 (Ar-CH-p), 117.0 (C-9), 113.0 (C-4b), 99.5 (C-
4a), 95.8 (C-3); MS (Fab, 70 eV,%): m/z 497 (M+2, 34), 495 (M+2, 100), 89 (22). Anal. Calcd. for 
C28H14ClNO6: C, 67.84; H, 2.85; N, 2.82. Found: C, 67.77; H, 2.99; N, 2.76. 
4.2. Biological activity assessment 
4.2.1. Anticancer activity 
The methodology of the NCI anticancer screening has been described in details at 
(http://www.dtp.nci.nih.gov). Briefly, the primary anticancer assay was performed against the 
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NCI-60 panel of approximately 60 human tumor cell lines, derived from nine neoplastic 
diseases, in accordance with the protocol of the Developmental Therapeutics Program, National 
Cancer Institute, Bethesda. In the one-dose screen, cells were seeded into 96-well plates at 
densities between 5 000 and 40 000 cells (depending on the doubling time of the cell line) and 24 
h later the test compounds were added to the culture at a single concentration (10 -5 M) for 48 h. 
End point determinations were made spectrophotometrically, based on the protein binding dye, 
sulforhodamine B (SRB). Results for each tested compound were reported as the percent of 
growth of the treated cells when compared to the untreated control cells and to the number of 
cells at time zero. A growth percent value between 0 and 100 indicates growth inhibition, e.g. a 
growth percent of 30 corresponds to 70% growth inhibition; negative values indicate lethality 
(lower cell number than at time zero), with -30% meaning 30% lethality.  
The cytotoxic and/or growth inhibitory effects of the most active compounds in the one-dose 
screen were tested in vitro at five different concentrations ranging from 10 -4 to 10-8 M (five-dose 
screen). Seven absorbance measurements for each cell line were made: time zero (Tz), control 
growth in the absence of drug (C), and test growth in the presence of the drug at the five 
concentration levels (Ti)]. The percentage growth was calculated at each of the drug 
concentrations levels. Percentage growth inhibition was calculated as: [(Ti - Tz)/(C -Tz)] x 100 
for concentrations for which Ti ≥ Tz, and as [(Ti - Tz)/Tz] x 100 for concentrations for which Ti 
< Tz. Three-dose response parameters were calculated for each compound. Growth inhibition of 
50% (GI50) was calculated from [(Ti - Tz)/(C - Tz)] x 100 = 50, which is the drug concentration 
resulting in a 50% lower net protein increase in the treated cells (measured by SRB staining) as 
compared to the net protein increase seen in the control cells. The drug concentration resulting in 
total growth inhibition (TGI) was calculated from Ti = Tz. The LC50 (concentration of drug 
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resulting in a 50% reduction in the measured protein at the end of the drug treatment as 
compared to that at the beginning), indicating a net loss of cells following treatment, was 
calculated from [(Ti - Tz)/Tz] x 100  = -50. Values were calculated for each of these three 
parameters if the level of activity was reached; however, if the effect was not reached, the value 
for that parameter was expressed as more than the maximum concentration tested. The lowest 
values are obtained with the most sensitive cell lines.  
4.2.2. Biochemistry 
Expression, Purification and Activation of MAP Kinases – Activated ERK2 (Rattus norvegicus 
mitogen activated protein kinase 1, GenBank accession number NM_053842) was expressed, 
purified and activated as previously reported in Kaoud et. al [33]. Activated ERK1 were 
expressed, purified and activated as mentioned in Callaway et al [47].  Full length human 
JNK2α2 (GenBank accession number NM_002752) was expressed and purified following 
previously published protocol [48, 49]. p38MAPKα was expressed, purified and activated as 
described previously [50]. The activated kinases were all stored in buffer [25 mM HEPES (pH 
7.5), 50 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, 2 mM DTT and 10-20% (v/v) glycerol] at -80 
ºC. 
Expression, Purification of protein substrates His-Ets-1 (1-138), GST-C-Jun (1-221) and 
GST-ATF2 (1-115) - His-Ets-1 (1-138) was expressed and purified according to Kaoud et. al 
previously published protocol [33].   GST-c-Jun (1-221) was expressed and purified according to 
Yan et al method [49]. GST-ATF2 (1-115) was expressed and purified according to Szafranska 
et al protocol [50]. 
Kinase activity assay – MAP kinase assays were performed following Kaoud et al previously 
reported method [51]. To summarize, all assays were conducted at 28-30 °C in kinase assay 
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buffer (25 mM HEPES buffer-pH 7.5, 50 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, 2 mM DTT, 
11 mM MgCl2 and 10 μg mL
-1 BSA) containing different concentrations of each inhibitor with a 
final DMSO concentration of 5%. To estimate the IC50 of each tested inhibitor towards the 
activity of different MAP kinases, 2 nM active ERK1 or ERK2 was assayed with 10 µM Ets1 (1-
138) protein substrate.  20 nM active JNK2α2 was assayed with 2 µM GST-c-Jun (1–221) as 
protein substrate. 10 nM active p38MAPKα, was assayed with 10 µM GST-ATF2 (Δ 1-115) 
protein substrate. In all  
the assays, the reaction was started by the addition of radio labeled 10 or 100 μM [γ-32P] ATP  
 (100-1000 c.p.m. pmol-1). In order to estimate the IC50 of each tested inhibitor, dose-response 
curves for data confirming to inhibition were fitted to equation 1.  
The parameters used in deriving equation 1 are defined as follows; i, concentration of inhibitor I; 
, observed rate;  , is the observed rate in the absence of inhibitor,  is the observed rate 
constant at saturating inhibitor, I,  is the concentration that leads to half the maximal change 
in . 
Steady-state kinetic experiments – All assays were performed as described in the kinase activity 
assay section and as previously reported by Kaoud et al [51], the concentrations of Mg-ATP and 
compound 6 were varied at fixed Ets-1 concentration level of Km. Plots of the product against 
time were employed to calculate the initial rate for each tested condition. Reciprocal plots of 1/v 



































Equation  2 
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Prism software where the kinetic data were globally fitted to equation 2;  
The parameters used in deriving equation 2 are defined as follows; , observed rate; , 
apparent maximum rate; s, concentration of substrate S; , apparent Michaelis constant for 
substrate S; i, concentration of inhibitor I; , apparent competitive inhibition constant for 
inhibitor I. 
4.2.3. Anticancer activity assays: 
Cell culture – BRAF-mutant A375 melanoma cell line was maintained in RPMI media 
(Invitrogen) containing 10% (v/v) heat inactivated FBS-US grade (Invitrogen), 1X Glutamax 
(Invitrogen), 100 UmL-1 penicillin and 100 gmL-1 streptomycin (Invitrogen). Cells was incubated 
in a humidified 5% CO2 incubator at 37 °C.   
Viability assays – To estimate the effect of each tested inhibitor on A375 cell viability, 2000 
cells were seeded in each well of 96 well plate, cells were treated with different doses of each 
compound and incubated for 72 hours before performing the MTS assay (CellTiter 96® 
AQueous One Solution Cell Proliferation Assay from Promega) following the manufacturer 
assay. All experiments were done in triplicate. 
Colony formation assay – For every tested inhibitor, 1000 A375 cells were seeded in each 60 
mm TC plate. Cells were incubated for 24 hours to adhere then treated with different doses of 
each compound and incubated for additional 10-14 days. Plates were washed with 1X PBS, fixed 
by 4% paraformaldehyde for 15 minutes at room temperature, washed with PBS then stained 
with 0.2% crystal violet in 20% methanol/80% water for 10 more minutes. Plates were washed 
excessively by distilled water then imaged under microscope. 
Western Blotting - For Western blotting, cells were seeded at 1000,000 cells per well in a 6-












compound for 4 or 12 hours. Cells were induced with 100 nM EGF for 10-15 minutes before 
lysis. Cells were washed by 1X PBS (Invitrogen) then lysates were prepared in M-PER ™ 
Mammalian Protein Extraction Reagent (Thermo-Fisher). After centrifuging the lysates, the 
protein concentration of each supernatant was estimated using Bradford analysis (Bio-Rad). 60 
µg of each lysate were fractionated on a 10% SDS polyacrylamide gel (Bio-Rad) and transferred 
to Hybond-P PVDF Membrane (GE Healthcare). Primary antibodies were incubated overnight at 
4 ºC using 1:1000 anti-phospho-p90RSK (Thr573) rabbit polyclonal Abs (Cell Signaling 
Technology); 1:1000 anti- RSK1/RSK2/RSK3 (32D7) Rabbit mAb (Cell Signaling Technology); 
1:200 anti-phospho-Elk-1 (Ser-383), rabbit polyclonal IgG (Santa Cruz Biotechnology, Inc); 
1:2000 anti-phospho-p44/42 MAPK (ERK1/2) (Thr202/Tyr204) (E10) mouse mAb (Cell 
Signaling Technology); 1:1000 anti p44/42 MAPK (ERK1/2) (137F5) rabbit mAb (Cell 
Signaling Technology); 1:2000 anti-phospho-SAPK/JNK (Thr183/Tyr185) (G9) mouse mAb 
(Cell Signaling Technology); 1:1000 anti-PARP (46D11) rabbit mAB (Cell Signaling 
Technology); 1:1000 anti-cleaved-PARP (D214) rabbit polyclonal Abs (Cell Signaling 
Technology); 1/2000 anti-Vinculin (E1E9V) XP rabbit mAb (Cell Signaling Technology) and 
1:5000 anti-actin, clone 4 mouse mAb (Millipore). Either anti-rabbit (Bio-Rad) or anti-mouse 
(Cell Signaling Technology) horseradish peroxidase-conjugated secondary antibodies and 
Western Bright ECL Western Blotting Reagents (Advansta) were used to develop the blots. All 
experiments were reproduced in independent experiments. All experiments were performed two 
times. 
Incucyte proliferation assay – 2000 A375 cells were seeded in each well of 96 well plate. Cells 
were incubated for 24 hours to adhere then treated with different doses of each inhibitor and 
incubated and analyzed using Incucyte ZOOM microscope (image recorder every 1 hour with a 
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10X objective). The real time growth confluence was estimated plotted using GraphPad Prism 
software. 
IncuCyte Apoptosis assay - 2000 A375 cells were seeded in each well of 96 well plate. Cells 
were incubated for 24 hours to adhere then treated with different doses of each inhibitor plus 
constant concentration of the lncuCyte Caspase-3/7 reagent ) following the manufacturer 
protocol. Cells were incubated and imaged in the lncuCyte® ZOOM equipment with a × 10 
objective at indicated time points. Number of apoptotic cells was normalized to the percentage 
area coverage (confluency) at the final time point to account for cell proliferation.  
4.3. Computational Methodology 
The crystal structure of ERK2 receptor complexed with N-[(1S)-1-(3-chloro-
4-fluorophenyl)-2-hydroxyethyl]-2-(tetrahydro-2H-pyran-4-ylamino)-5,8-dihydropyrido[3,4-d]p
yrimidine-7(6H)-carboxamide (2SH) (PDB code: 4OE6 [41]) was taken as the template for all 
docking calculations. Modeller software [52] was used to construct and refine the missing 
residues (177-187,202-204 and 331-333). The protonation state of the protein was predicted 
using H++ server [53]. All molecular docking calculations were carried out using Autodock4.2 
software [54]. The pdbqt file for ERK2 was prepared according to the AutoDock protocol [55]. 
All docking parameters were kept to their default values. However, the number of GA runs was 
set to 250 and the maximum number of energy evaluation was set to 25,000,000. The docking 
grid was selected to encompass the ATP-active site of ERK2 receptor with a grid size of 70 Å × 
70 Å × 70 Å and a spacing value of 0.375 Å. The atomic charges of inhibitors were calculated 
by gasteiger method [56]. The grid center was placed at 16.20, 7.50, 12.40 (XYZ coordinates). 
Prior to molecular docking, the 3D structures of the studied compounds were energetically 
minimized using MMFF94S force field with the help of SZYBKI software [57].  
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4.4. Crystal Structure Determinations 
The single-crystal X-ray diffraction study were carried out on a Bruker D8 Venture 
diffractometer with Photon100 detector at 123(2) K using Cu-K radiation ( = 1.54178 Å 
for 3c, 3f) and Mo-K radiation ( = 0.71073 Å for 6). Direct Methods for 3c, 3f 
(SHELXS-97)[58] and dual space methods for 6 (SHELXT)[59] were used for structure 
solution and refinement was carried out using SHELXL-2014 (full-matrix least-squares on 
F2).[58] Hydrogen atoms were localized by difference electron density determination and 
refined using a riding model (H(N, O) free). Semi-empirical absorption corrections were 
applied. 
3c: yellow crystals, C19H8BrNO4 ∙ C2H6OS, Mr = 472.30, crystal size 0.18 × 0.12 × 0.03 
mm, triclinic, space group P-1 (No. 2), a = 7.3950(2) Å, b = 10.0211(3) Å, c = 13.8015(4) 
Å, α = 70.268(1)°, β = 78.915(1)°, γ = 79.360(1)°, V = 936.79(5) Å3, Z = 2, ρ = 1.674 Mg/m-
3, µ(Cu-Kα) = 4.347 mm
-1, F(000) = 476, 2max = 144.2°, 14049 reflections, of which 3661 
were independent (Rint = 0.032), 267 parameters, 1 restraint, R1 = 0.026 (for 3325 I > 2σ(I)), 
wR2 = 0.065 (all data), S = 1.05, largest diff. peak / hole = 0.352 / -0.359 e Å
-3. 
3f: yellow crystals, C21H13NO4, Mr = 343.32, crystal size 0.26 × 0.06 × 0.04 mm, 
monoclinic, space group P21/c (No. 14), a = 8.0265(3) Å, b = 12.3658(5) Å, c = 15.3573(6) 
Å, β = 93.529(2)°, V = 1521.38(10) Å3, Z = 4, ρ = 1.499 Mg/m-3, µ(Cu-Kα) = 0.864 mm
-1, 
F(000) = 712, 2max = 144.2°, 15270 reflections, of which 2991 were independent (Rint = 
0.024), 235 parameters, R1 = 0.034 (for 2800 I > 2σ(I)), wR2 = 0.091 (all data), S = 1.06, 
largest diff. peak / hole = 0.229 / -0.249 e Å-3. 
6: orange crystals, C28H14ClNO6 ∙ ½ (C3H7NO), Mr = 532.40, crystal size 0.40 × 0.30 × 0.20 
mm, triclinic, space group P-1 (No. 2), a = 10.8841(4) Å, b = 12.3025(5) Å, c = 19.4831(8) 
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Å, α = 108.007(1)°, β = 104.210(1)°, γ = 92.144(1)°, V = 2386.89(16) Å3, Z = 4, ρ = 1.482 
Mg/m-3, µ(Mo-Kα) = 0.213 mm
-1, F(000) = 1096, 2max = 55.0°, 48590 reflections, of which 
10949 were independent (Rint = 0.027), 702 parameters, 2 restraints, R1 = 0.043 (for 9320 I 
> 2σ(I)), wR2 = 0.117 (all data), S = 1.04, largest diff. peak / hole = 0.875 / -0.459 e Å
-3 (in 
the solvent dmf).  
CCDC 1542037 (3c), CCDC 1539309 (3f), and 1539310 (6) contain the supplementary 
crystallographic data for this paper. These data can be obtained free of charge from The 
Cambridge Crystallographic Data Centre via www.ccdc.cam.ac.uk/data_request/cif.  
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